Just_Super/E+ via Getty Images Investment Thesis When I first wrote about Seagate Technology Holdings ( STX ), the big idea was simple. That HAMR would matter. And AI would create more storage demand. And STX would be one of the cleanest beneficiaries. In one of the earlier pieces , I more or less said that HAMR was great for business. And I still believe that. But the story has changed in an impo...
Just_Super/E+ via Getty Images Investment Thesis When I first wrote about Seagate Technology Holdings ( STX ), the big idea was simple. That HAMR would matter. And AI would create more storage demand. And STX would be one of the cleanest beneficiaries. In one of the earlier pieces , I more or less said that HAMR was great for business. And I still believe that. But the story has changed in an important way. There is no longer a "wait for the roadmap" thesis. It is now a "the roadmap is showing up in production, margins and customer commitments "thesis. And that is exactly why I am reiterating STX with a Strong Buy rating. The fresh part of my thesis is not that Seagate has better technology. It is that the company now looks like a supply assurance asset inside AI infrastructure. I mean, management mentioned that nearline capacity is fully allocated through 2026. And the orders for the H1 2027 are about to open. Yet there are customers that are already discussing 2028 demand. And in my view, that is unusually strong visibility for a storage hardware company. Now if I add that to the fact that Mozaic 4+ is now qualified and in production with two leading hyperscale cloud providers, with capacities of up to 44TB. Then one would start to see some real shift. STX is moving from a cyclical HDD company into a business with better pricing discipline, stronger mix and much cleaner and clear earnings power than investors used to give it credit for. And I am saying this because the numbers already back that up. In 2Q 2026 for instance, STX posted $2.83Bn revenue, while the non-GAAP margin stood at 42.2%, non-GAAP operating margin on the other side was 31.9% and non-GAAP EPS sat at $3.11. FCFs came in at $607Mn and management called it the highest in over 8 years. Then it also guided for 3Q 2026 revenue to come in at $2.9Bn and noted that operating margin should approach the 30% range. In my opinion that is a financial profile of a company that is climbing into a richer part of...
An 89-year-old Hong Kong man has been rescued after he was discovered clinging to the exterior wall of a care home in To Kwa Wan following a fall from a second-floor window. Care home staff filed a report with the police at around 8am on Thursday, stating that the man was hanging from the wall. The building is located at the intersection of Lok Shan Road and Ma Tau Wai Road. The force said the man...
An 89-year-old Hong Kong man has been rescued after he was discovered clinging to the exterior wall of a care home in To Kwa Wan following a fall from a second-floor window. Care home staff filed a report with the police at around 8am on Thursday, stating that the man was hanging from the wall. The building is located at the intersection of Lok Shan Road and Ma Tau Wai Road. The force said the man fell from the window while trying to retrieve something and clung to a section of the wall near an...
Palantir (NASDAQ: PLTR) has been one of the most popular artificial intelligence (AI) stocks since the AI arms race began in 2023. Its AI platform has become more and more popular with each passing quarter, leading to huge growth for the stock. But is it the ultimate hypergrowth stock? Let's take a look, because the answer may surprise you. Image source: The Motley Fool. Continue reading
Palantir (NASDAQ: PLTR) has been one of the most popular artificial intelligence (AI) stocks since the AI arms race began in 2023. Its AI platform has become more and more popular with each passing quarter, leading to huge growth for the stock. But is it the ultimate hypergrowth stock? Let's take a look, because the answer may surprise you. Image source: The Motley Fool. Continue reading
Earnings Call Insights: PEDEVCO Corp. (PED) Q4 2025 Management View CEO, President & Director John Schick framed 2025 as “a transformational year” and said the October 31, 2025 Juniper merger created “a scaled Rockies-focused energy platform,” highlighting a shift from “approximately 1,500 barrels of oil equivalent per day” to “a combined rate that averaged over 5,300 BOE per day in the fourth qua...
Earnings Call Insights: PEDEVCO Corp. (PED) Q4 2025 Management View CEO, President & Director John Schick framed 2025 as “a transformational year” and said the October 31, 2025 Juniper merger created “a scaled Rockies-focused energy platform,” highlighting a shift from “approximately 1,500 barrels of oil equivalent per day” to “a combined rate that averaged over 5,300 BOE per day in the fourth quarter.” Schick said proved reserves “nearly doubled to 32.1 million BOE or approximately $27 per share on a post-split basis,” and emphasized scope and optionality: “We hold over 310,000 net acres across the D-J Basin, Powder River Basin and Permian Basin with an approximately 88% liquids mix and well over a decade of identified inventory.” Schick pointed to insider ownership and Juniper’s role, stating, “Insiders, including the management team own a significant majority of PEDEVCO,” and that Juniper “invested approximately $18.6 million of new equity at the merger.” COO Reagan Dukes detailed a post-merger cost program: “we have identified around $10 million to $13 million in capital projects that we believe will drive meaningful lease operating expense or LOE reductions,” adding, “We expect these projects to reduce our LOE by up to $1 million per month, equating to $10 million to $12 million in annual savings.” CFO, Treasurer and Principal Accounting & Financial Officer Robert Long summarized Q4 scale as reported: “We generated $23.1 million of revenue, $15.4 million of adjusted EBITDA and production of 483,159 BOE.” Outlook CFO Robert Long guided, “we are projecting full year 2026 adjusted EBITDA of $60 million to $70 million,” adding that the range is “based on average realized oil prices of $65 per barrel and average realized gas prices of $3.50 per Mcf.” Long clarified scope and potential upside: “It assumes the base production profile plus the benefit of our cost optimization work. It does not assume incremental operated development beyond what has been planned. If we ...
Luis Alvarez The Trump administration plans to impose tariffs on pharmaceutical companies that haven't agreed to lower U.S. drug prices, with an announcement expected as soon as Thursday, Bloomberg reported, citing people familiar with the matter. The president had earlier threatened to impose tariffs ranging from 100% to 200% on the pharmaceutical industry as part of a broader push to bring drug ...
Luis Alvarez The Trump administration plans to impose tariffs on pharmaceutical companies that haven't agreed to lower U.S. drug prices, with an announcement expected as soon as Thursday, Bloomberg reported, citing people familiar with the matter. The president had earlier threatened to impose tariffs ranging from 100% to 200% on the pharmaceutical industry as part of a broader push to bring drug manufacturing back to the U.S. and lower prices for American patients.The proposed tariffs stem from an investigation under Section 232 of the Trade Expansion Act, which permits trade restrictions based on national security concerns. The companies that have neither entered into agreements nor are actively negotiating with the administration could face tariffs of up to 100%, the people added. The plans aren’t yet final and could still change, and there could also be exemptions for some medicines and disease categories, the report added . Major drugmaker companies that already struck pricing deals and agreed to lower U.S. drug prices or invest locally are Pfizer ( PFE ), AstraZeneca ( AZN ), Eli Lilly ( LLY ), Novo Nordisk ( NVO ), Bristol Myers Squibb ( BMY ), GSK ( GSK ), Sanofi ( SNY ), and Novartis ( NVS ), among others. Pharma and healthcare ETFs: SPDR S&P Pharmaceuticals ETF ( XPH ), iShares U.S. Pharmaceuticals ETF ( IHE ), and VanEck Pharmaceutical ETF ( PPH ), iShares Biotechnology ETF ( IBB ), SPDR S&P Biotech ETF ( XBI ), Health Care Select Sector SPDR Fund ( XLV ), Vanguard Health Care ETF ( VHT ). Dear readers : We recognize that politics often intersects with the financial news of the day, so we invite you to click here to join the separate political discussion. More on pharmas How Reserve Management Purchases Have Eased Money Market Rates Implications From Japan's March Rate Decision I'm Not Buying Tuesday's 'Hopium' Rally SA analyst flags rising risks as stocks climb on Iran optimism Healthcare among laggards in Q1; MRNA and DVA lead gainers while HUM drags